Announced Tue, 14 Jul · 11:45 IST
BALAXI PHARMA clarifies Q4 FY26 filing errors; standalone profit up 43 percent
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.0%1-day move
₹24.38
prior close
—
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+0.0-2.3-0.8-0.8-3.6+0.5————
Up moveDown movePending
AI summary
Company responded to NSE on XBRL and PDF mismatches in Q4 FY26 results: a typo in employee benefit expense and a sign error in consolidated other comprehensive income. Revised filings submitted. Standalone FY26 revenue rose 32 percent to Rs 8,085 lakhs and net profit up 43 percent to Rs 515 lakhs. Consolidated revenue fell 8 percent to Rs 27,017 lakhs. Board noted Jadcherla formulation plant received manufacturing licence.
Likely market impact
Filing errors were administrative only; underlying numbers stand. Strong standalone growth plus new Jadcherla manufacturing licence are positive signals going forward.